Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis.

PloS one - 1 Jan 2013

Mori Seiji, Tran Vu, Nishikawa Kyoko, Kaneda Teruya, Hamada Yoshinosuke, Kawaguchi Naomasa, Fujita Masaaki, Saegusa Jun, Takada Yoko K, Matsuura Nariaki, Zhao Min, Takada Yoshikazu

Abstract excerpt

Fibroblast growth factor-1 (FGF1) and FGF2 play a critical role in angiogenesis, a formation of new blood vessels from existing blood vessels. Integrins are critically involved in FGF signaling through crosstalk. We previously reported that FGF1 directly binds to integrin αvβ3 and induces FGF receptor-1 (FGFR1)-FGF1-integrin αvβ3 ternary complex. We previously generated an integrin binding defective FGF1 mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aorta
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chick Embryo

Share to Colonic Neoplasms

Share to Endothelial Cells

Share to Fibroblast Growth Factor 1

Share to Integrins

Share to Neovascularization, Pathologic

Source

Open in PubMed Open full text

Identifiers

PMID: 23469107
DOI: 10.1371/journal.pone.0057927
PMCID: PMC3585250

Genes

FGF1
FGF2
FGFR1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis.PMID 23469107Read ↗

Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.Semantic proximity Read ↗

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?Semantic proximity Read ↗

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.Semantic proximity Read ↗

Integrin signaling in tumor biology: mechanisms of intercellular crosstalk and emerging targeted therapiesSemantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-BSemantic proximity Read ↗

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read ↗

Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approachSemantic proximity Read ↗

Integrin β1 is an essential factor in vasculogenic mimicry of human cancer cellsSemantic proximity Read ↗

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.Semantic proximity Read ↗

Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.Semantic proximity Read ↗

Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.